PL372490A1 - 5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej - Google Patents

5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej

Info

Publication number
PL372490A1
PL372490A1 PL03372490A PL37249003A PL372490A1 PL 372490 A1 PL372490 A1 PL 372490A1 PL 03372490 A PL03372490 A PL 03372490A PL 37249003 A PL37249003 A PL 37249003A PL 372490 A1 PL372490 A1 PL 372490A1
Authority
PL
Poland
Prior art keywords
phtalide
propionylamino
trifluoromethylphenyl
cyclopropyl
hydroxy
Prior art date
Application number
PL03372490A
Other languages
English (en)
Inventor
Norbert Schmees
Manfred Lehmann
Ulrike Fuhrmann
Peter Muhn
Christa Hegele-Hartung
Michael Klotzbücher
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02005530A external-priority patent/EP1344776A1/en
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL372490A1 publication Critical patent/PL372490A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
PL03372490A 2002-03-11 2003-03-10 5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej PL372490A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36304402P 2002-03-11 2002-03-11
EP02005530A EP1344776A1 (en) 2002-03-11 2002-03-11 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders

Publications (1)

Publication Number Publication Date
PL372490A1 true PL372490A1 (pl) 2005-07-25

Family

ID=27806515

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372490A PL372490A1 (pl) 2002-03-11 2003-03-10 5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej

Country Status (26)

Country Link
US (1) US7388006B2 (pl)
EP (1) EP1482925B1 (pl)
JP (1) JP2005526064A (pl)
CN (1) CN1652768A (pl)
AR (1) AR035904A1 (pl)
AU (1) AU2003209720A1 (pl)
BR (1) BR0308394A (pl)
CA (1) CA2478948A1 (pl)
CR (1) CR7490A (pl)
DE (1) DE60311236T2 (pl)
DK (1) DK1482925T3 (pl)
ES (1) ES2280766T3 (pl)
HR (1) HRP20040923A2 (pl)
IL (1) IL164032A0 (pl)
MX (1) MXPA04008881A (pl)
NO (1) NO20044279L (pl)
NZ (1) NZ535427A (pl)
PE (1) PE20040157A1 (pl)
PL (1) PL372490A1 (pl)
PT (1) PT1482925E (pl)
RS (1) RS89504A (pl)
RU (1) RU2314299C2 (pl)
TW (1) TW200307674A (pl)
UA (1) UA78027C2 (pl)
UY (1) UY27715A1 (pl)
WO (1) WO2003075915A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US7408060B2 (en) 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
KR101025139B1 (ko) * 2005-12-09 2011-03-31 에프. 호프만-라 로슈 아게 항염증제로서의 프로피온아미드 화합물
EP1963287A1 (en) * 2005-12-09 2008-09-03 F.Hoffmann-La Roche Ag Glucocorticoid receptor modulators as antiinflammatory agents
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
DE102006061913A1 (de) * 2006-12-21 2008-06-26 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
CN101289408B (zh) * 2007-04-18 2013-02-27 中国科学院上海药物研究所 非甾体类孕激素受体调节剂及其制备方法、药物组合物和用途
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然複合ホルモン補充製剤および療法
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3062732C (en) * 2017-05-10 2023-08-01 Ventana Medical Systems, Inc. Stabilized two-part hematoxylin solution utilizing ph adjustment
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
NO312255B1 (no) * 2000-06-28 2002-04-15 Pgs Reservoir Consultants As Verktöy for gjennomhulling av et langsgående veggparti av et fôringsrör
DE10038639A1 (de) * 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
AU2002219218A1 (en) * 2000-12-28 2002-07-16 Schering Ag Method for screening for progesterone receptor isoform-specific ligands

Also Published As

Publication number Publication date
AU2003209720A1 (en) 2003-09-22
DE60311236D1 (de) 2007-03-08
NO20044279L (no) 2004-12-08
MXPA04008881A (es) 2004-12-07
TW200307674A (en) 2003-12-16
BR0308394A (pt) 2005-01-25
AR035904A1 (es) 2004-07-28
RU2004130430A (ru) 2005-08-10
US20030232824A1 (en) 2003-12-18
UA78027C2 (en) 2007-02-15
CN1652768A (zh) 2005-08-10
ES2280766T3 (es) 2007-09-16
DK1482925T3 (da) 2007-05-14
US7388006B2 (en) 2008-06-17
IL164032A0 (en) 2005-12-18
HRP20040923A2 (en) 2004-12-31
CR7490A (es) 2006-02-07
JP2005526064A (ja) 2005-09-02
CA2478948A1 (en) 2003-09-18
WO2003075915A1 (en) 2003-09-18
RS89504A (en) 2006-10-27
DE60311236T2 (de) 2008-02-14
NZ535427A (en) 2006-08-31
EP1482925B1 (en) 2007-01-17
RU2314299C2 (ru) 2008-01-10
UY27715A1 (es) 2003-08-29
EP1482925A1 (en) 2004-12-08
PT1482925E (pt) 2007-04-30
PE20040157A1 (es) 2004-06-03

Similar Documents

Publication Publication Date Title
PL372490A1 (pl) 5-{2-hydroksy-3-[1-(3-trifluorometylofenylo)-cyklopropylo]-propionyloamino}-ftalid i związki pokrewne o aktywności modulującej receptor progesteronowy do stosowania w kontroli płodności i hormonalnejterapii zastępczej
AU2003228283A1 (en) Quinazolinone modulators of nuclear receptors
HUP0204291A3 (en) Use of composition containing estrogen and drospirenone for hormone replacement therapy
MXPA00012306A (es) Usos medicos de un modulador de receptor de estrogeno selectivo en combinacion con precursores esteroides sexuales.
CN105120808A (zh) 颈托
HK1098943A1 (en) Diaper product, supply information management system, use information management system, and diaper product management system
EP1483050A4 (en) REGULATED CRYSTALLINE (111) FACE EXPOSURE CATALYSTS
EE200100053A (et) Biogeensete östrogeensulfamaatide kasutamine hormoonasendusraviks
GB2402519B (en) Power supply management system and related program therefor
AU2003296895A8 (en) Combination therapy for controlling appetites
IL163947A0 (en) Methods/devices for regulating patient's temperature
AU2003213957A1 (en) Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
EP1902691B8 (de) Osteoporose-Orthese
SI1482925T1 (sl) 5-(2-hidroksi-3-(1-(trifluorometilfenil)-ciklopropil)-propionilamino)- ftalid in sorodne spojine z aktivnostjo moduliranja progesteronskega receptorja za uporabo pri kontroli plodnosti in hormonski nadomestni terapiji
WO2004105581A3 (en) Removable cartridge for a microdermabrasion unit
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
NZ508039A (en) Synergistic therapeutic combinations of a selective estrogen receptor modulator and a parathyroid hormone
TWI370773B (en) Monofilament for use in screen gauze and screen gause using the same
NO20076683L (no) Cyanopyrrol-sulfonamid progesteron reseptormodulatorer og deres anvendelse
PL375629A1 (pl) Związki 1-fenylo-2-dimetyloaminometylocykloheksanu do terapii objawów depresyjnych, bólu i nietrzymania
SI1635843T1 (sl) Terapija, ki vsebuje dienogest, za hormonsko nadomestitev in depresijo
AU2003285271A1 (en) Device for the diagnosis and/or therapy of functional disorders of the cervical spine
AU2002368326A1 (en) Hormone replacement therapy with drospirenone
DK0889727T3 (da) Sekventiel estrogen/progesteron-antagonist-kombination til hormonerstatningsterapien
AU2003211605A1 (en) Self regulating system for human resources management

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)